ViroLogic plans further PhenoSense tests:
This article was originally published in Clinica
Executive Summary
ViroLogic, which manufactures the PhenoSense HIV drug resistance test, plans to commercialise a PhenoSense assay for entry inhibitors, a new class of anti-HIV drug, by the end of this year. The company says that research has shown that susceptibility to entry inhibitors varies widely among patients who have not yet been exposed to the drugs. ViroLogic, based in South San Francisco, California, is also planning to make a PhenoSense assay for viral fitness (ability to replicate) available for research use by the end of the year, and for clinical use in the first half of 2002.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.